(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors...
Stats | |
---|---|
本日の出来高 | 321 167 |
平均出来高 | 707 477 |
時価総額 | 359.41M |
EPS | $0 ( 2024-03-13 ) |
次の収益日 | ( $-0.560 ) 2024-06-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.480 |
ATR14 | $0.00900 (0.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-03 | Redmile Group, Llc | Sell | 59 986 | Cash-settled Swaps |
2024-02-01 | Redmile Group, Llc | Sell | 19 700 | Cash-settled Swaps |
2024-02-01 | Redmile Group, Llc | Buy | 205 483 | Cash-settled Swaps |
2024-01-31 | Redmile Group, Llc | Buy | 150 000 | Cash-settled Swaps |
2024-01-29 | Redmile Group, Llc | Buy | 150 000 | Cash-settled Swaps |
INSIDER POWER |
---|
-45.66 |
Last 79 transactions |
Buy: 1 817 492 | Sell: 5 217 316 |
ボリューム 相関
ADC Therapeutics SA 相関
10 最も負の相関 | |
---|---|
FLRT | -0.949 |
SLB | -0.944 |
CANE | -0.944 |
OII | -0.943 |
IEZ | -0.94 |
OIH | -0.937 |
WHD | -0.937 |
HAL | -0.935 |
AFT | -0.934 |
BKR | -0.933 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
ADC Therapeutics SA 相関 - 通貨/商品
ADC Therapeutics SA 財務諸表
Annual | 2023 |
収益: | $69.56M |
総利益: | $67.03M (96.36 %) |
EPS: | $-2.94 |
FY | 2023 |
収益: | $69.56M |
総利益: | $67.03M (96.36 %) |
EPS: | $-2.94 |
FY | 2022 |
収益: | $209.91M |
総利益: | $205.33M (97.82 %) |
EPS: | $-1.990 |
FY | 2021 |
収益: | $33.92M |
総利益: | $32.52M (95.89 %) |
EPS: | $-3.52 |
Financial Reports:
No articles found.
ADC Therapeutics SA
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。